Showing results (1991-2000 of 2,694) with videos related to

Sort By:
Pageof 270
The Lancet. Infectious Diseases|August 12, 2024
Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trialPaul Kim, Ana M Sanchez, Taylor J R Penke, et al.
The Lancet. Infectious Diseases|May 18, 2025
The pharmacokinetics of antibiotics in patients with obesity: a systematic review and consensus guidelines for dose adjustmentsAnne-Grete Märtson, Katie E Barber, Ryan L Crass, et al.
The Lancet. Infectious Diseases|April 26, 2025
Safety and efficacy of single-dose primaquine to interrupt Plasmodium falciparum malaria transmission in children compared with adults: a systematic review and individual patient data meta-analysisDaniel Yilma, Kasia Stepniewska, Teun Bousema, et al.
The Lancet. Infectious Diseases|March 21, 2025
Safety and effectiveness of MVA-BN vaccination against mpox in at-risk individuals in Germany (SEMVAc and TEMVAc): a combined prospective and retrospective cohort studyDavid Hillus, Ngoc Han Le, Pinkus Tober-Lau, et al.
The Lancet. Infectious Diseases|March 22, 2025
Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9-14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trialTsiri Agbenyega, Anne E Schuind, Samuel Adjei, et al.
The Lancet. Infectious Diseases|March 13, 2025
Exploring parvovirus B19 pathogenesis and therapy among kidney transplant recipients: case report and review of literatureGian Marco Berti, Elisabetta Manaresi, Gisella Vischini, et al.
The Lancet. Infectious Diseases|March 24, 2025
Tuberculosis preventive therapy: scientific and ethical considerations for trials of ultra-short regimensTimothy M Walker, James A Watson, David A J Moore, et al.
The Lancet. Infectious Diseases|March 2, 2025
Zika virus: advancing a priority research agenda for preparedness and responseEve M Lackritz, Lee-Ching Ng, Ernesto T A Marques, et al.
The Lancet. Infectious Diseases|May 31, 2024
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trialCissy Kityo, Ivan K Mambule, Joseph Musaazi, et al.
The Lancet. Infectious Diseases|June 3, 2024
Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studiesNicole Bézay, Laura Wagner, Vera Kadlecek, et al.
Pageof 270